ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1091

Synergistic Immunoregulatory Effects of IL-10 and TGF-β on Humoral Immunity

Toshihiko Komai1, Tomohisa Okamura1,2, Mariko Inoue1, Yukiko Iwasaki1, Kaoru Morita1, Kazuhiko Yamamoto1 and Keishi Fujio1, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Max Planck-The University of Tokyo Center for Integrative Inflammology, The University of Tokyo, Tokyo, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: B cell targeting, immunoregulation, systemic lupus erythematosus (SLE) and transforming growth factor, T-Regulatory Cells

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: B Cell Biology and Targets in Autoimmune Disease - Poster I: SLE and Sjögren's

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  We have previously identified CD4+CD25–Foxp3– regulatory T cells (Treg) that characteristically express lymphocyte-activation gene 3 (LAG3) produce IL-10. Recently we reported that these Treg regulate humoral immunity and ameliorate lupus pathologies in MRL/lprmice with producing large amounts of TGF-β3. However, the immunological significance of the co-existence of IL-10 and TGF-β3 has not been elucidated. Here we examined the synergistic role of IL-10 and TGF-β3 in the control of lupus pathogenesis.

Methods: In vivo, 4-hydroxy-3-nitrophenylacetyl (NP)- keyhole limpet hemocyanin (KLH) immunized C57BL/6 mice were intravenously injected with plasmid pCAGGS-Mock, pCAGGS-Il10, pCAGGS-Tgfb1, or pCAGGS-Tgfb3 vectors. NP-specific antibody titers were quantified by ELISA. Lupus-prone MRL/lpr mice were also injected with each pCAGGS-Mock, pCAGGS-Tgfb1, or pCAGGS-Tgfb3 vectors and comparative analyses of splenomegaly, autoantibody production, and renal pathology were conducted. In vitro, B cells stimulated with lipopolysaccharides (LPS) were cultured in the presence or absence of IL-10 and TGF-β3, and the proliferation and antibody production were assessed. Further, the comprehensive gene expression analyses by next generation sequencing (NGS) analysis and immunoblotting in each condition were conducted.

Results:  NP-specific IgG antibody titer was significantly suppressed in NP-KLH immunized mice only in cases with simultaneous administration of pCAGGS-Il10 and pCAGGS-Tgfb3. In MRL/lpr mice whose serum IL-10 levels were quite higher than MRL/+ mice, not pCAGGS-Tgfb1, but pCAGGS-Tgfb3 ameliorated lupus-like phenotypes, such as splenomegaly, glomerulonephritis, and anti-dsDNA antibody production. In in vitroexperiments, although LPS stimulated B cells either with IL-10 or TGF-β3 enhanced the proliferation and antibody production, conversely, the simultaneous addition of IL-10 and TGF-β3 suppressed them. Hierarchical clustering of NGS data revealed that the genes of “stimulated B cells with IL-10 and TGF-β3” and “no stimulated B cells”, but not “stimulated B cells either with IL-10 or TGF-β3”, located within the same cluster. Immunoblot analyses confirmed the specific down-regulation of mammalian target of rapamycin (mTOR) target molecules in “stimulated B cells with IL-10 and TGF-β3”.

Conclusion: We revealed that IL-10 and TGF-β3 synergistically suppressed humoral immune responses through suppressing mTOR signaling. Also, in lupus pathology, TGF-β3 exhibited the superior therapeutic effects compared to TGF-β1. The combination of IL-10 and TGF-β, especially TGF-β3, could be a novel therapeutic approach to systemic autoimmune diseases including lupus.


Disclosure: T. Komai, Chugai, 2; T. Okamura, Chugai, 2; M. Inoue, Chugai, 2; Y. Iwasaki, Chugai, 2; K. Morita, Chugai, 2; K. Yamamoto, Bristol-Myers Squibb, 2,Takeda, 2,Chugai, 2,AbbVie, 7,Astellas, 7,Daiichi-Sankyo, 7,MitsubishiTanabe, 7,Pfizer Inc, 7,Sanofi, 7,Santen, 7,Teijin, 7,Boehringer Ingelheim, 7,Eisai, 7,Ono, 7,Taisho Toyama, 7,UCB., 7,ImmunoFuture, 7,Asahi Kasei, 7,Janssen Pharmaceutica Product, L.P., 7; K. Fujio, Bristol-Myers Squibb, 2,Chugai, 2,Takeda, 2,Daiichi-Sankyo, 7,MitsubishiTanabe, 7,Pfizer Inc, 7,Santen, 7,Eisai, 7,Taisho Toyama, 7,UCB., 7,Janssen Pharmaceutica Product, L.P., 7.

To cite this abstract in AMA style:

Komai T, Okamura T, Inoue M, Iwasaki Y, Morita K, Yamamoto K, Fujio K. Synergistic Immunoregulatory Effects of IL-10 and TGF-β on Humoral Immunity [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/synergistic-immunoregulatory-effects-of-il-10-and-tgf-%ce%b2-on-humoral-immunity/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/synergistic-immunoregulatory-effects-of-il-10-and-tgf-%ce%b2-on-humoral-immunity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology